Adult Dosing
Secondary amenorrhea
- 5-10 mg PO Daily x 5-10 days; start at any time in cycle
Dysfunctional uterine bleeding
- 5-10 mg PO Daily x 5-10 days starting on day 16 or day 21 of menstrual cycle
Reduction of endometrial hyperplasia; postmenopausal women receiving estrogen
- Monophasic regimen: 2.5-5 mg PO Daily with 0.625 mg conj. estrogens
- Biphasic regimen: 5-10 mg PO Daily for 12-14 consecutive days per month with 0.625 mg conj. estrogens
Pediatric Dosing
- Safety and efficacy in pediatrics have not been established
[Outline]
- An increased risk of stroke, deep vein thrombosis (DVT), pulmonary embolism, and MI has occurred with estrogen plus progestin therapy. On occurrence or suspicion of these events immediately discontinue estrogen plus progestin therapy. Appropriately manage risk factors for arterial vascular disease and/or venous thromboembolism, obesity and systemic lupus erythematosus
- Increased risk of stroke have occurred in women receiving daily conjugated estrogens (CE 0.625 mg) plus medroxyprogesterone acetate (MPA 2.5mg) compared to women receiving placebo
- Risk of coronary heart disease and venous thromboembolism (VTE) is associated with this drug
- Risk of breast cancer may increase with duration of use and appear to return to baseline in about 5 yrs after ceasing therapy. Increase in abnormal mammograms may occur; further evaluation is essential in such case. Perform yearly breast examinations in women and advise them to perform monthly breast self-examinations. Schedule mammography examinations based on patient age, risk factors, and prior mammogram results
- Increased risk of endometrial cancer may occur with duration of use. Risk may increase 15-24 folds for 5-10 yrs or more. Risk may persist for at least 8-15 yrs after discontinuation of therapy
- Undertake adequate diagnostic measures, including endometrial sampling when essential to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal vaginal bleeding
- Increased risk for development of ovarian cancer exists
- Dementia may occur in patients undergoing therapy with this drug
- Discontinue medication pending examination on sudden partial or complete loss of vision, or a sudden onset of proptosis, diplopia or migraine. Permanently discontinue therapy if examination reveals papilledema or retinal vascular lesions
- Increased risk of breast cancer, adverse effects on lipoprotein metabolism (lowering HDL, raising LDL) and impairment of glucose tolerance may occur with the use of progestins with estrogens
- Undertake adequate diagnostic measures in cases of undiagnosed abnormal vaginal bleeding
- Monitor blood pressure at regular intervals
- Plasma triglycerides may be elevated leading to pancreatitis and other complications in patients with pre-existing hypertriglyceridemia
- Exercise caution in patients having a history of cholestatic jaundice associated with past estrogen use or with pregnancy. Discontinue medication on recurrence of such event
- Edema may occur. Carefully observe patients who have conditions which might be influenced by this factor, such as cardiac or renal dysfunction
- Exacerbation of asthma, diabetes mellitus, epilepsy, migraine, porphyria, systemic lupus erythematosus, and hepatic hemangiomas may occur. Use cautiously in women with these conditions
- Increased risk of minor birth defects may occur in children whose mothers were exposed to progestins during the first trimester of pregnancy
- Monitor BP, pap smear, pelvic examination at baseline; then q12 month; and monitor serum triglycerides and glucose closely on presence of diabetes mellitus
- Severe hypercalcemia has been reported
Cautions: Use cautiously in
Pregnancy Category:X
Breastfeeding: Medroxyprogesterone acetate is considered the hormonal contraceptive of choice during all stages of lactation. Does not does not adversely affect the composition of milk, the growth and development of the infant, or the milk supply. Administration sooner than 3 days postpartum may inhibit lactogenesis and interfere with the establishment of lactation. It is prudent to administer this drug no sooner than 3 days postpartum when lactation is established. This information is based upon Lactmed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 25 March 2011). Manufacturer suggests to avoid using this drug during lactation.
US Trade Name(s)
US Availability
medroxyprogesterone (generic)
Provera
Canadian Trade Name(s)
- Apo-medroxy
- Gen-medroxy
- Medroxy
- Novo-medrone
- Provera
- Provera Pak
Canadian Availability
medroxyprogesterone (generic)
Apo-medroxy, Provera
Gen-medroxy, Novo-medrone
Medroxy
Provera Pak
UK Trade Name(s)
UK Availability
Climanor
Provera
- TABS: 2.5, 5, 10, 100, 200, 400 mg
Australian Trade Name(s)
- Medroxyhexal
- Provera
- Ralovera
Australian Availability
Medroxyhexal
Provera
- TABS: 2.5, 5, 10, 100, 200, 250, 500 mg
Ralovera
[Outline]
Pricing data from www.DrugStore.com in U.S.A.
- Provera 2.5 MG TABS [Bottle] (PFIZER U.S.)
30 mg = $37.79
90 mg = $97.62 - Provera 10 MG TABS [Bottle] (PFIZER U.S.)
30 mg = $62.99
90 mg = $178.48 - Provera 5 MG TABS [Bottle] (PFIZER U.S.)
30 mg = $50.39
90 mg = $142.78
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
65 yrs of age during 4 yrs of therapy with daily CE 0.625 mg combined with MPA 2.5 mg, relative to placebo has occurred